{"title":"Narratives of Gene Patenting","authors":"J. Contreras","doi":"10.2139/SSRN.2485681","DOIUrl":null,"url":null,"abstract":"The debate over gene patenting in the United States has been ongoing for nearly three decades. It reached a climax in June 2013, with the Supreme Court's decision in Assn. for Molecular Pathology v. Myriad Genetics. The Myriad case was remarkable for many reasons, not least because it fostered the engagement of hundreds of scientists, physicians, patients, lawyers, activists and policy makers, each of whom expressed a view regarding the case and gene patenting, more generally. From this multitude of voices emerged six distinct narrative types that recounted the \"facts\" in the case. I have termed these the Science, Innovator, Administrative, Access, Dystopian and Congestion narratives. In this article, I trace the origins of each of the narrative types in Myriad from press accounts, published literature and the record in the case, including nearly one hundred separate amicus briefs filed at all stages of the litigation. I then assess how each narrative type influenced and became incorporated into the resulting judicial decisions. There is a strong correlation between the narrative types employed by a speaker and the normative case outcome desired by that speaker. This correlation occurs not only when the narrators are litigants or amici curiae, but also judges. This finding suggests that the judges issuing decisions in the case calibrated the narratives or \"facts\" expressed in their opinions to align best with the doctrinal outcomes that they desired.The six narrative types that emerged in Myriad also constitute at least a partial taxonomy of narrative types within the broader realm of disputes involving new technology, scientific discovery and innovation. Thus, whether a dispute involves gene patenting, genetically modified organisms, nanotechnology or self-driving vehicles, it is likely that some or all of the narrative types in the Myriad case will make an appearance. However, the same narrative types in different technological settings do not always appear to support the same doctrinal outcomes. Thus, narrative type cannot be said to be determinative of case outcome without additional context provided by the narrator’s perspective, audience and worldview.","PeriodicalId":81266,"journal":{"name":"Florida State University law review. Florida State University. College of Law","volume":"22 1","pages":"1133-1200"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Florida State University law review. Florida State University. College of Law","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/SSRN.2485681","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
The debate over gene patenting in the United States has been ongoing for nearly three decades. It reached a climax in June 2013, with the Supreme Court's decision in Assn. for Molecular Pathology v. Myriad Genetics. The Myriad case was remarkable for many reasons, not least because it fostered the engagement of hundreds of scientists, physicians, patients, lawyers, activists and policy makers, each of whom expressed a view regarding the case and gene patenting, more generally. From this multitude of voices emerged six distinct narrative types that recounted the "facts" in the case. I have termed these the Science, Innovator, Administrative, Access, Dystopian and Congestion narratives. In this article, I trace the origins of each of the narrative types in Myriad from press accounts, published literature and the record in the case, including nearly one hundred separate amicus briefs filed at all stages of the litigation. I then assess how each narrative type influenced and became incorporated into the resulting judicial decisions. There is a strong correlation between the narrative types employed by a speaker and the normative case outcome desired by that speaker. This correlation occurs not only when the narrators are litigants or amici curiae, but also judges. This finding suggests that the judges issuing decisions in the case calibrated the narratives or "facts" expressed in their opinions to align best with the doctrinal outcomes that they desired.The six narrative types that emerged in Myriad also constitute at least a partial taxonomy of narrative types within the broader realm of disputes involving new technology, scientific discovery and innovation. Thus, whether a dispute involves gene patenting, genetically modified organisms, nanotechnology or self-driving vehicles, it is likely that some or all of the narrative types in the Myriad case will make an appearance. However, the same narrative types in different technological settings do not always appear to support the same doctrinal outcomes. Thus, narrative type cannot be said to be determinative of case outcome without additional context provided by the narrator’s perspective, audience and worldview.
在美国,关于基因专利的争论已经持续了近30年。2013年6月,随着最高法院对分子病理学协会(Assn. for Molecular Pathology)诉麦利亚德遗传学(Myriad Genetics)一案的裁决,这一问题达到了高潮。Myriad案之所以引人注目,有很多原因,尤其是因为它促进了数百名科学家、医生、患者、律师、活动家和政策制定者的参与,他们每个人都对此案和更广泛的基因专利表达了自己的观点。从众多的声音中,出现了六种不同的叙述类型,叙述了案件中的“事实”。我把它们称为科学叙事、创新者叙事、管理叙事、访问叙事、反乌托邦叙事和拥堵叙事。在这篇文章中,我从媒体报道、出版的文献和案件记录,包括在诉讼的各个阶段提交的近百份不同的法庭之友简报,追溯了《Myriad》中每一种叙事类型的起源。然后,我评估了每种叙事类型是如何影响并被纳入最终的司法决定的。说话者使用的叙述类型与说话者期望的规范性结果之间存在很强的相关性。这种关联不仅发生在叙述者是诉讼当事人或法庭之友的时候,也发生在法官的时候。这一发现表明,在案件中作出判决的法官对他们意见中表达的叙述或“事实”进行了校准,以使其最符合他们所期望的理论结果。麦利亚德案中出现的六种叙事类型至少也构成了涉及新技术、科学发现和创新的更广泛争议领域中叙事类型的部分分类。因此,无论争端涉及基因专利、转基因生物、纳米技术还是自动驾驶汽车,麦利亚德案中的部分或全部叙事类型都可能出现。然而,在不同的技术背景下,相同的叙事类型似乎并不总是支持相同的理论结果。因此,如果没有叙述者的视角、受众和世界观提供的额外语境,叙述类型就不能说是案件结果的决定性因素。